Microplate Dx – a University of Strathclyde spin out

Microplate Dx is a multi-award-winning diagnostics company spun out of the University of Strathclyde, which is dedicated to developing novel solutions to tackle the global health threat of antimicrobial resistance (AMR). Their mission is to accelerate treatment decisions and improve patient quality of life through pioneering diagnostics that enable effective antimicrobial stewardship.  

Microplate Dx was co-founded by Dr Stuart Hannah, Dr Poonam Malik, Professor Damion Corrigan and Professor Paul Hoskisson, who bring together a wealth of expertise in biotechnology, microbiology, business strategy, and biosensor technology.

The company’s patented RapidPlateTM diagnostic technology utilises sensitive biosensor electrodes modified with miniaturised hydrogel deposits containing various antibiotics tailored to the specific infection type, which could be bacterial, fungi, viruses or parasites.  

A clinical feasibility study with the NHS demonstrated the technology’s capability to identify the optimal antibiotic for a particular infection in under one hour. Initially focusing on urinary tract infections, Microplate Dx plans to expand its platform to address a broader range of infectious diseases, meeting significant clinical needs.

By ensuring patients receive the correct antibiotic treatment promptly, Microplate Dx aims to prevent and control the spread of AMR worldwide, positioning itself at the forefront of efforts to combat this critical global health challenge. 

Dr Stuart Hannah, CEO, Microplate Dx said:

“Rapid diagnosis of the appropriate antibiotic treatment avoids lengthy delays in antibiotic prescribing, meaning patients suffering a life-threatening infection can be treated straightaway when the infection first presents, and start to recover much more quickly than with conventional methods. We call this ‘personal prescribing’, and for serious infections early intervention can save lives.  

Leah Pape, Head of High Growth Services, Scottish Enterprise said: 

“Antibiotic resistance is a major global health risk and the company’s innovative testing technology has the potential to be both life-saving and world-changing.”